Nectar Lifesciences Quarterly Results for Trading Insights
Latest Quarter Net Profit
₹-176 Cr
QSept 2025
In Sept 2025, Nectar Lifesciences (NECLIFE) reported revenue ₹0 Cr and net profit ₹-176 Cr. View Nectar Lifesciences 52-week for the annual high/low range and current price position.
NECLIFE Quarterly Results — Revenue, Profit & EPS Highlights
Nectar Lifesciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates.
- Net Profit of ₹-176 Cr in Sept 2025 (-35.4% vs Mar 2025, -3033.3% vs Sept 2024)
- EBITDA of ₹-176 Cr in Sept 2025 (-12.8% vs Mar 2025)
- Earnings Per Share of ₹-7.85 in Sept 2025 (-35.3% vs Mar 2025)
Nectar Lifesciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
NECLIFE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 0 | 429 | 6 | 89 | 12 | - | - |
| Net Profit (₹ Cr) | -176 | -130 | -63 | 14 | 6 | - | - |
| EBITDA (₹ Cr) | -176 | -156 | -63 | 34 | 6 | - | - |
| EPS (₹) | -7.85 | -5.80 | -2.82 | 0.64 | 0.25 | - | - |
| Operating Margin (%) | 0.0% | -36.0% | -1212.0% | 0.0% | -10.0% | - | - |
NECLIFE Share Price Trend — 1-Year Movement Across Quarterly Results
Nectar Lifesciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Nectar Lifesciences share price chart.
Revenue Trend (₹ Cr)
Dec 2025
89
Jun 2025
6
Mar 2025
429
Sept 2025
0
Net Profit Trend (₹ Cr)
Dec 2025
14
Jun 2025
-63
Mar 2025
-130
Sept 2025
-176
Operating Margin Trend (%)
Dec 2025
0.0%
Jun 2025
-1212.0%
Mar 2025
-36.0%
Sept 2025
0.0%
NECLIFE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Nectar Lifesciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹415,924.72 Cr | 1808.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 139.1 |
|
Divis Laboratories
Sept 2025 |
₹171,625.44 Cr | 6502.5 | 2,860 | 689 | +7.1% | - | 24.1% | 250.4 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹142,059.09 Cr | 4185.1 | 3,219 | 591 | +11.3% | - | 18.4% | 238.6 |
|
Dr Reddys Laborator…
Sept 2025 |
₹110,348.15 Cr | 1322.9 | 9,135 | 1,337 | +1.1% | - | 14.6% | 81.8 |
|
Cipla
Sept 2025 |
₹105,996.98 Cr | 1309.6 | 7,716 | 1,353 | +12.0% | - | 17.5% | 78.3 |
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores
All amounts in ₹ Crores